| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal | 상세 |
| RO-7204239 | GYM-329; RO-7204239; RG-6237; RG-70240 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal | 상세 |
| Trevogrumab | REGN-1033; REGN1033; SAR-391786; GDF8 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Obesity; Sarcopenia | 상세 |
| AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne | 상세 |
| KER-065 | KER-065; RKER-065 | Phase 1 Clinical | Keros Therapeutics Inc | Neuromuscular Diseases; Obesity | 상세 |
| HS135 | HS-135 | Phase 1 Clinical | 35Pharma Inc | Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension | 상세 |